Search - tctmd.com

Displaying 421 - 440 of 2051

Sort: Relevancy | Date

Presentation TCT 2015

Rationale for and Design of HORIZONS-ABSORB

Presenter: Dariusz Dudek, Robert J. de Winter, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Five-Year Results From the EXAMINATION Trial

Presenter: Dariusz Dudek, Robert J. de Winter, Manel Sabate

October 11, 2015

Presentation TCT 2015

Outcomes After Contemporary DES in STEMI: Glass Half Full or Half Empty?

Presenter: Dariusz Dudek, Robert J. de Winter, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Bioresorbable Scaffolds in STEMI: Rationale and 1-Year TROFI II Results

Presenter: Dariusz Dudek, Robert J. de Winter, Patrick W. Serruys

October 11, 2015

Presentation TCT 2015

Specialized Stents in STEMI: MGuard From MASTER I to MASTER II

Presenter: Dariusz Dudek, Robert J. de Winter, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Has the Case for Radial Intervention in STEMI Been Proven Beyond Doubt? The Case for and Against (an Internal Debate)

Presenter: Dariusz Dudek, Robert J. de Winter, Ajay J. Kirtane

October 11, 2015

Presentation TCT 2015

Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL)

Presenter: Dariusz Dudek, Robert J. de Winter, Stefan K. James

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Presenter: C. Michael Gibson, Marco Valgimigli, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Presenter: C. Michael Gibson, Marco Valgimigli, Harvey D. White

October 11, 2015

Presentation TCT 2015

STEMI: Treatment Strategies, Drugs, and Devices

Presenter: Tayo A. Addo, Dharam J. Kumbhani

October 11, 2015

Presentation TCT 2015

Case Resolution: How Did We Treat Our STEMI Patient With Multivessel Disease (and What Were the Long-term Outcomes)?

Presenter: Thomas Engstroem, Barry D. Rutherford, Henning Kelbæk

October 11, 2015

Presentation TCT 2015

Case Introduction: A STEMI Patient With Multivessel Disease

Presenter: Thomas Engstroem, Barry D. Rutherford, Henning Kelbæk

October 11, 2015

Presentation TCT 2015

Obtaining Informed Consent in Difficult Scenarios Case 1: Patient Presenting With STEMI

Presenter: David A. Cox, Thomas D. Stuckey, Timothy D. Henry

October 11, 2015

Presentation TCT 2015

Impact of CTO Revascularization After Primary PCI for AMI: Is This Where the Benefit Lies?

Presenter: Thomas Engstroem, Barry D. Rutherford, David Antoniucci

October 11, 2015

Presentation TCT 2015

Nonculprit Lesions in STEMI Patients With Multivessel Disease: Is the Issue Ischemia or Vulnerable Plaque?

Presenter: Thomas Engstroem, Barry D. Rutherford, David Erlinge

October 11, 2015

Advertisement

Rationale for and Design of HORIZONS-ABSORB

Five-Year Results From the EXAMINATION Trial

Outcomes After Contemporary DES in STEMI: Glass Half Full or Half Empty?

Bioresorbable Scaffolds in STEMI: Rationale and 1-Year TROFI II Results

Specialized Stents in STEMI: MGuard From MASTER I to MASTER II

Has the Case for Radial Intervention in STEMI Been Proven Beyond Doubt? The Case for and Against (an Internal Debate)

Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL)

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

STEMI: Treatment Strategies, Drugs, and Devices

Case Resolution: How Did We Treat Our STEMI Patient With Multivessel Disease (and What Were the Long-term Outcomes)?

Case Introduction: A STEMI Patient With Multivessel Disease

Obtaining Informed Consent in Difficult Scenarios Case 1: Patient Presenting With STEMI

Impact of CTO Revascularization After Primary PCI for AMI: Is This Where the Benefit Lies?

Nonculprit Lesions in STEMI Patients With Multivessel Disease: Is the Issue Ischemia or Vulnerable Plaque?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content